triple negative breast cancer
Conditions
Interventions
2:Capecitabine combined with TCM placebo
Sponsors
China-Japan Friendship Hospital,
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Women aged 18-70; (2) Patients with stage II-III triple-negative breast cancer with definite pathological diagnosis who planned to receive capecitabine adjuvant intensive therapy within 6 months after the completion of standard adjuvant chemoradiotherapy; (3) Syndrome differentiation is syndrome of deficiency of spleen and kidney combined with mutual obstruction of phlegm and blood stasis; Or the constitution type is Yang deficiency qi deficiency combined with qi stagnation and blood stasis; (4) ECOG score 0-2; (5) Agree to participate in this study and sign informed consent.
Exclusion criteria
Exclusion criteria: (1) complicated with other malignant tumors or serious diseases of heart, liver, kidney and hematopoietic system; (2) pregnant and lactating women; (3) patients with a history of mental illness who cannot cooperate; (4) patients known to be allergic to the study drug; (5) patients undergoing other drug trials; (6) The clinician judged that the patient was receiving other treatments that affected the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| estimated 3-year disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year distant disease-free survival;estimated 3-year overall survival;3-year locoregional recurrence-free survival; | — |
Countries
China
Contacts
Public ContactDonggui Wan
Outcome results
None listed